Tal Keinan

Managing Partner

2016

Dynamic Loop Capital is Sir Ronald Cohen's private investment vehicle, selectively investing in and supporting socially responsible and disruptive technology companies. The fund looks for extraordinary teams with purposeful missions and a strong technological edge, aiming to dramatically impact society at large. Our investments: Allegro.AI - Computer Vision Deep Learning Platform - https://allegro.ai/ Alpha Tau - Alpha Radiation Cancer Treatment - https://www.alphatau.com/ ClearX - B2B Settlement and Clearing Network - https://www.clearx.io/ Visby Medical - Handheld PCR - https://www.visbymedical.com/ ContinUse Biometrics - No Touch Health Monitoring Solution - https://www.cu-bx.com/ Custodia.ai - Corporate Expense Management Solution - https://www.custodia.ai/ First - Blockchain Financial Infrastructure Service - https://www.firstdag.com/ Lumen - Hack your Metabolism - https://www.lumen.me/ Nym Health - Autonomous Clinical Coding Solution - https://nym.health/ OptiBus - Public Transportation Optimization Software - https://www.optibus.com/ Papaya Global - Global Payroll Management Solution - https://papayaglobal.com/ RiseUp - Cashflow Management - https://www.riseup.co.il/ Stoke - On Demand Talent Management Solution - https://www.stoke.world/ Voyager Labs - Deep Insight Engine for Enterprises - https://voyagerlabs.co/

Board Member

2018

Board Observer

2017

Board Observer

2017

Board Member

2018

Board Member

2016

Zoey changes the way businesses create sophisticated online stores. Built from Magento, Zoey has one of the most powerful feature sets of any eCommerce platform in the world, yet it's affordable and easy to use. Now anyone can leverage a modern, flexible and intuitive eCommerce solution that is full of big features. Get to know Zoey by signing up for a free trial at Zoey.com!

Member of the Advisory Board (Acquired by Innovid)

2016 - 2017

Taykey is a technology company that analyzes hundreds of millions of data points per day to discover what's trending for audiences and how those interests change over time. Taykey’s solutions provide companies with intelligence surrounding the brands, people, products, and events most relevant to their target audiences and the ability to automatically align their digital advertising with those trends in real-time. Founded in 2009, the company is headquartered in New York with offices in Herzliya (Israel), and San Francisco. Learn more at www.taykey.com.

Co-Founder and CEO

2007 - 2017

Establishing a great team, and working along side with the the most amazing individuals. Raising money from private and institutional investors, and signing deals with clients.

Advisor

2014 - 2016

Crosswise provides the world's most accurate and authoritative device map, anonymously matching billions of PCs, tablets and smartphones to their individual users. This data enables ad tech vendors, consumer brands and premium publishers to realize the tremendous benefits of cross-device advertising, content personalization and analytics. Crosswise employs ad tech industry veterans, big data software engineers, and the world's largest team of data scientists dedicated exclusively to solving cross-device identification challenges. For further information, visit www.crosswise.com. On April 21, 2016, Oracle completed the acquisition of Crosswise. Oracle Data Cloud is the fastest growing global Data as a Service business, aggregating more than 3 billion profiles from over 15 million websites in its data marketplace and operating the most accurate ID Graph to enable understanding of consumer behavior across all media channels. The addition of Crosswise further broadens the Oracle ID Graph to construct a complete view of consumers' digital interactions across multiple devices. Learn more about Oracle and Crosswise at www.oracle.com/crosswise

Associate

2004 - 2007

Member of the Risk Department of Morgan Stanley. Started in Market Risk, covering risk portfolios and scenario analysis. Later moved to the Credit Risk Deparment where I conducted full credit analysis as part of a due diligence process on Morgan Stanley’s counterparties.